

Docket

Docket No.: 58508-011

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of

Hyun Chul LEE, et al.

Serial No.: 09/706,690

Group Art Unit: 1646

Filed: November 07, 2000

Examiner: Unknown

For: TREATMENT OF DIABETES USING SINGLE CHAIN INSULIN ANALOG

**SUBMISSION OF SEQUENCE LISTING
AND PRELIMINARY AMENDMENT**

Commissioner for Patents
Washington, DC 20231


Sir:

In response to the Notice to Comply with Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated
February 2, 2001, please amend the above-identified application as follows:

IN THE SPECIFICATION

Please replace second full paragraph at page 8 with the following new paragraph:

The polypeptide linker connects the C-terminus of the B chain to the N-terminus of the A chain. The linker may be of any length so long as the linker provides the structural conformation necessary for SIA to have a glucose uptake and insulin receptor binding effect. Preferably, the linker is about 5-18 amino acids long. Preferably, it is 6-12 amino acids long. Even more preferably, it is 6-9 amino acids long. Most preferably it is 7 amino acids long. The most preferred sequence for the linker are Gly-Gly-Gly-Pro-Gly-Lys-Arg (SEQ ID NO:1) or Arg-Arg-Gly-Pro-Gly-Gly-Gly (SEQ ID NO:2). However, it should be understood that many variations of this sequence are possible such as in the length (both addition and deletion) and substitutions of amino acids without



11/a
M.G.
2/20/02